AzTrials
AzTrials

Gastric CancerNCT03909997

Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer

An observational study of Gastric Cancer and Esophagogastric Junction Disorder, run by Hospital Dr Sotero del Rio at 1 site in Chile.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Gastrectomy is the main treatment for gastric and Siewert type II-III esophagogastric junction (EGJ) cancer. This surgery is associated with significant morbidity. The aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications. Read more about this study

Who is it for?
Ages 18 years and older
How many people
300 participants
Where
1 siteChile
Study dates
5 Apr 2019to 5 Apr 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: All consecutive patients treated with a gastrectomy for gastric cancer or esophagogastric cancer at a single center are included.

Who may be able to join

  • Patients treated with a gastrectomy for gastric cancer or esophagogastric cancer.
  • Confirmed adenocarcinoma histology.

Who cannot join

  • Histology different from adenocarcinoma.

Trial locations and contacts

1 site in 1 country.

Enrique M Norero, MD contact

56-2-3536601

enorero@yahoo.com

Paulina Gonzalez, RN contact

56-2-3536601

pauly_gc@hotmail.com

Chile1 site, 1 recruiting

  • Hospital Sotero del Rio

    Santiago, RM, 7501064

    Enrique M Norero, MD, 56-2-3536601, enorero@yahoo.com

    Recruiting

Other trials in Chile

About this study

Official title: Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer: Perioperative Results and Long Term Survival

Gastrectomy is the main treatment for gastric and Siewert type II-III esophagogastric junction (EGJ) cancer. This surgery is associated with significant morbidity. The aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications. This is a retrospective cohort study.

Read the detailed description

Gastrectomy is the main treatment for gastric and Siewert type II-III esophagogastric junction (EGJ) cancer. This surgery is associated with significant morbidity. The aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications.

This was a retrospective cohort study. The investigators included patients treated with gastrectomy for gastric or EGJ cancers at a single center. Severe morbidity was defined as Clavien-Dindo score ≥3.

The following factors are analyzed: age, sex, comorbidity, American Society of Anesthesiologists (ASA) physical status, tobacco and alcohol consumption, body mass index (BMI), hematocrit, serum albumin level, tumor location, the use of preoperative chemotherapy, laparoscopic or open surgery, total or subtotal gastrectomy, duodenal stump closure, multi-organ resection, lymphadenectomy, reconstruction method, T status, lymph node metastasis, and resection margin. The T stage was grouped by T1-T2 and T3-T4 for analysis. Patients will be followed for 5 years after surgery for survival analysis. A multivariate analysis is performed to identify predictors of overall and severe morbidity; and predictors of long-term survival.

Keywords
Stomach neoplasms, gastrectomy, Risk factors, morbidity, adenocarcinoma
Medical subject headings
Stomach Neoplasms, Adenocarcinoma

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients with severe 30-day or in-hospital morbidity

    Clavien 3 or higher complications

    Measured: Perioperative

Secondary outcomes (1)

  1. Median and percentage of patients with long-term survival

    5 year survival

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Apr 2019
  2. Study start5 Apr 2019
  3. Primary completion5 Apr 2021 (estimated)
  4. Study completion5 Apr 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03909997
Sponsor's protocol ID
1
Status last verified
Apr 2019
First submitted
6 Apr 2019
Last updated
11 Apr 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005 Sep;92(9):1099-102. doi: 10.1002/bjs.4952.

    PubMed 15931657

  • Onate-Ocana LF, Cortes-Cardenas SA, Aiello-Crocifoglio V, Mondragon-Sanchez R, Ruiz-Molina JM. Preoperative multivariate prediction of morbidity after gastrectomy for adenocarcinoma. Ann Surg Oncol. 2000 May;7(4):281-8. doi: 10.1007/s10434-000-0281-9.

    PubMed 10819368

  • Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery. 2014 Aug;156(2):298-304. doi: 10.1016/j.surg.2014.03.022. Epub 2014 Mar 16.

    PubMed 24947651

  • Kim TH, Suh YS, Huh YJ, Son YG, Park JH, Yang JY, Kong SH, Ahn HS, Lee HJ, Slankamenac K, Clavien PA, Yang HK. The comprehensive complication index (CCI) is a more sensitive complication index than the conventional Clavien-Dindo classification in radical gastric cancer surgery. Gastric Cancer. 2018 Jan;21(1):171-181. doi: 10.1007/s10120-017-0728-3. Epub 2017 Jun 8.

    PubMed 28597328

  • Lee KG, Lee HJ, Yang JY, Oh SY, Bard S, Suh YS, Kong SH, Yang HK. Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien-Dindo system. J Gastrointest Surg. 2014 Jul;18(7):1269-77. doi: 10.1007/s11605-014-2525-1. Epub 2014 May 13.

    PubMed 24820136

  • Kikuchi H, Miyata H, Konno H, Kamiya K, Tomotaki A, Gotoh M, Wakabayashi G, Mori M. Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry. Gastric Cancer. 2017 Nov;20(6):987-997. doi: 10.1007/s10120-017-0706-9. Epub 2017 Mar 11.

    PubMed 28285387

  • Norero E, Vega EA, Diaz C, Cavada G, Ceroni M, Martinez C, Briceno E, Araos F, Gonzalez P, Baez S, Vinuela E, Caracci M, Diaz A. Improvement in postoperative mortality in elective gastrectomy for gastric cancer: Analysis of predictive factors in 1066 patients from a single centre. Eur J Surg Oncol. 2017 Jul;43(7):1330-1336. doi: 10.1016/j.ejso.2017.01.004. Epub 2017 Feb 10.

    PubMed 28359594

  • Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.

    PubMed 15273542

  • Hayashi T, Yoshikawa T, Aoyama T, Ogata T, Cho H, Tsuburaya A. Severity of complications after gastrectomy in elderly patients with gastric cancer. World J Surg. 2012 Sep;36(9):2139-45. doi: 10.1007/s00268-012-1653-6.

    PubMed 22610266

  • Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.

    PubMed 26352529

  • Climent M, Hidalgo N, Vidal O, Puig S, Iglesias M, Cuatrecasas M, Ramon JM, Garcia-Albeniz X, Grande L, Pera M. Postoperative complications do not impact on recurrence and survival after curative resection of gastric cancer. Eur J Surg Oncol. 2016 Jan;42(1):132-9. doi: 10.1016/j.ejso.2015.08.163. Epub 2015 Sep 3.

    PubMed 26385054

  • Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013 May;20(5):1575-83. doi: 10.1245/s10434-012-2720-9. Epub 2012 Oct 18.

    PubMed 23076557

  • Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014 Mar;21(3):891-8. doi: 10.1245/s10434-013-3384-9. Epub 2013 Nov 20.

    PubMed 24254205

Questions about this trial

What is this clinical trial studying?

An observational study of Gastric Cancer and Esophagogastric Junction Disorder, run by Hospital Dr Sotero del Rio at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Enrique M Norero, MD (56-2-3536601, enorero@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients with severe 30-day or in-hospital morbidity (time frame: Perioperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03909997, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in